Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 12,738 | 1,674 | 10,893 |
| Samples | 3,896 | 697 | 3,132 |
| Peptides | 3,826 | 648 | 3,320 |
Function
PCLO · Piccolo presynaptic cytomatrix protein
The protein encoded by this gene is part of the presynaptic cytoskeletal matrix, which is involved in establishing active synaptic zones and in synaptic vesicle trafficking. Variations in this gene have been associated with bipolar disorder and major depressive disorder. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2011].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 2500 amino-acid changes on canonical ENST00000333891 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PCLO · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PCLO – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 17/40 42% | 0/0 0% |
| Chronic Myelogenous Leukemia | 9/25 36% | 0/0 0% |
| Melanoma | 87/210 41% | 548/1899 29% |
| Non-Small Cell Lung Carcinoma | 105/304 35% | 201/1390 14% |
| Oral Cavity Carcinoma | 9/54 17% | 0/0 0% |
| Glioblastoma | 16/98 16% | 0/0 0% |
| Endometrial Carcinoma | 20/42 48% | 80/612 13% |
| Squamous Cell Lung Carcinoma | 14/57 25% | 103/810 13% |
| Gastric Carcinoma | 17/74 23% | 226/1809 12% |
| Hodgkins Lymphoma | 8/16 50% | 9/122 7% |
| Esophageal Carcinoma | 1/23 4% | 93/769 12% |
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| Acute Myeloid Leukemia | 10/90 11% | 0/0 0% |
| Colorectal Carcinoma | 55/143 38% | 313/3239 10% |
| Other Solid Cancers | 10/94 11% | 162/1515 11% |
| Hepatocellular Carcinoma | 10/46 22% | 212/2210 10% |
| Head and Neck Carcinoma | 11/85 13% | 146/1574 9% |
| Esophageal Squamous Cell Carcinoma | 20/51 39% | 214/2550 8% |
| Bladder Carcinoma | 4/58 7% | 81/956 8% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 11/133 8% |
| Cervical Carcinoma | 3/35 9% | 34/422 8% |
| Small Cell Lung Carcinoma | 1/9 11% | 60/752 8% |
| Unknown | 1/10 10% | 2/29 7% |
| Neuroendocrine Tumour | 29/154 19% | 26/577 5% |
| Plasma Cell Myeloma | 10/44 23% | 12/305 4% |
| Adrenocortical Carcinoma | 0/3 0% | 7/112 6% |
| Germ Cell Tumour | 5/25 20% | 5/169 3% |
| Other Sarcomas | 12/69 17% | 27/699 4% |
| B-Cell Non-Hodgkins Lymphoma | 25/88 28% | 108/2534 4% |
| Ovarian Carcinoma | 26/109 24% | 28/998 3% |
Mutation Distribution
Where PCLO is mutated · all tissues, split by cell line vs tissue
How many mutations in PCLO were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 12,738 mutations in PCLO
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|